Human Gene Module / Chromosome X / CNKSR2

CNKSR2connector enhancer of kinase suppressor of Ras 2

Score
3S
Suggestive Evidence, Syndromic Criteria 3.1, Syndromic
Autism Reports / Total Reports
1 / 4
Rare Variants / Common Variants
9 / 0
Aliases
CNKSR2, CNK2,  KSR2,  MAGUIN
Associated Syndromes
-
Genetic Category
Syndromic
Chromosome Band
Xp22.12
Associated Disorders
ASD, ID, EPS, ADHD
Relevance to Autism

Analysis of de novo variants identified in patients from the Deciphering Developmental Disorders (DDD) Study cohort, along with meta-analysis of probands from previously published studies, identified CNKSR2 as a gene exceeding genome-wide significance (P<7.0E-07) (Deciphering Developmental Disorders Study, 2017). Of the five cases with de novo loss-of-function variants in the CNKSR2 gene from the DDD cohort, two (DECIPHER IDs 260220 and 266616) were reported to have the Human Phenotype Ontology (HPO) term "Autism spectrum disorder".

Molecular Function

This gene encodes a multidomain protein that functions as a scaffold protein to mediate the mitogen-activated protein kinase pathways downstream from Ras. This gene product is induced by vitamin D and inhibits apoptosis in certain cancer cells. It may also play a role in ternary complex assembly of synaptic proteins at the postsynaptic membrane and coupling of signal transduction to membrane/cytoskeletal remodeling.

Reports related to CNKSR2 (4 Reports)
# Type Title Author, Year Autism Report Associated Disorders
1 Support Loss-of-Function CNKSR2 Mutation Is a Likely Cause of Non-Syndromic X-Linked Intellectual Disability. Houge G , et al. (2012) No ID, epilepsy/seizures, ADHD
2 Support Absent CNKSR2 causes seizures and intellectual, attention, and language deficits. Vaags AK , et al. (2014) No ID, epilepsy/seizures
3 Primary Prevalence and architecture of de novo mutations in developmental disorders. Deciphering Developmental Disorders Study (2017) No ASD
4 Support CNKSR2 mutation causes the X-linked epilepsy-aphasia syndrome: A case report and review of literature. Sun Y , et al. (2018) Yes -
Rare Variants   (9)
Status Allele Change Residue Change Variant Type Inheritance Pattern Parental Transmission Family Type PubMed ID Author, Year
- - copy_number_loss Familial Maternal Simplex 22511892 Houge G , et al. (2012)
- - copy_number_loss Familial Maternal Simplex 25223753 Vaags AK , et al. (2014)
- - copy_number_loss Familial Maternal Multiplex 25223753 Vaags AK , et al. (2014)
c.2185C>T p.Arg729Ter stop_gained De novo - Simplex 30397616 Sun Y , et al. (2018)
- - frameshift_variant De novo - - 28135719 Deciphering Developmental Disorders Study (2017)
c.1273C>T p.Gln425Ter stop_gained De novo - - 28135719 Deciphering Developmental Disorders Study (2017)
c.1733G>A p.Trp578Ter stop_gained De novo - - 28135719 Deciphering Developmental Disorders Study (2017)
c.2044+2T>A p.? splice_site_variant De novo - - 28135719 Deciphering Developmental Disorders Study (2017)
c.453dupA p.Asp152ArgfsTer8 frameshift_variant Familial Maternal Multiplex 25223753 Vaags AK , et al. (2014)
Common Variants  

No common variants reported.

SFARI Gene score
3S

Suggestive Evidence, Syndromic

3S

Score Delta: Score remained at 3.3 + S

3

Suggestive Evidence

See all Category 3 Genes

The literature is replete with relatively small studies of candidate genes, using either common or rare variant approaches, which do not reach the criteria set out for categories 1 and 2. Genes that had two such lines of supporting evidence were placed in category 3, and those with one line of evidence were placed in category 4. Some additional lines of "accessory evidence" (indicated as "acc" in the score cards) could also boost a gene from category 4 to 3.

The syndromic category includes mutations that are associated with a substantial degree of increased risk and consistently linked to additional characteristics not required for an ASD diagnosis. If there is independent evidence implicating a gene in idiopathic ASD, it will be listed as "#S" (e.g., 2S, 3S, etc.). If there is no such independent evidence, the gene will be listed simply as "S."

1/1/2017
icon
3S

Increased from to 3S

Description

Analysis of de novo variants identified in patients from the Deciphering Developmental Disorders (DDD) Study cohort, along with meta-analysis of probands from previously published studies, identified CNKSR2 as a gene exceeding genome-wide significance (P<7.0E-07) (Deciphering Developmental Disorders Study, 2017). Of the five cases with de novo loss-of-function variants in the CNKSR2 gene from the DDD cohort, two (DECIPHER IDs 260220 and 266616) were reported to have the Human Phenotype Ontology (HPO) term "Autism spectrum disorder". Other recurrent HPO terms used in cases with CNKSR2 variants were joint hypermobility, global developmental delay, and abnormality of the head.

Krishnan Probability Score

Score 0.59722958787948

Ranking 430/25841 scored genes


[Show Scoring Methodology]
Krishnan and colleagues generated probability scores genome-wide by using a machine learning approach on a human brain-specific gene network. The method was first presented in Nat Neurosci 19, 1454-1462 (2016), and scores for more than 25,000 RefSeq genes can be accessed in column G of supplementary table 3 (see: http://www.nature.com/neuro/journal/v19/n11/extref/nn.4353-S5.xlsx). A searchable browser, with the ability to view networks of associated ASD risk genes, can be found at asd.princeton.edu.
ExAC Score

Score 0.99974804937338

Ranking 809/18225 scored genes


[Show Scoring Methodology]
The Exome Aggregation Consortium (ExAC) is a summary database of 60,706 exomes that has been widely used to estimate 'constraint' on mutation for individual genes. It was introduced by Lek et al. Nature 536, 285-291 (2016), and the ExAC browser can be found at exac.broadinstitute.org. The pLI score was developed as measure of intolerance to loss-of- function mutation. A pLI > 0.9 is generally viewed as highly constrained, and thus any loss-of- function mutations in autism in such a gene would be more likely to confer risk. For a full list of pLI scores see: ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3.1/functional_gene_constraint/fordist_cle aned_exac_nonTCGA_z_pli_rec_null_data.txt
Sanders TADA Score

Score 0.94278057126092

Ranking 15436/18665 scored genes


[Show Scoring Methodology]
The TADA score ('Transmission and De novo Association') was introduced by He et al. PLoS Genet 9(8):e1003671 (2013), and is a statistic that integrates evidence from both de novo and transmitted mutations. It forms the basis for the claim of 65 individual genes being strongly associated with autism risk at a false discovery rate of 0.1 (Sanders et al. Neuron 87, 1215-1233 (2015)). The calculated TADA score for 18,665 RefSeq genes can be found in column P of Supplementary Table 6 in the Sanders et al. paper (the column headed 'tadaFdrAscSscExomeSscAgpSmallDel'), which represents a combined analysis of exome data and small de novo deletions (see www.cell.com/cms/attachment/2038545319/2052606711/mmc7.xlsx).
Zhang D Score

Score 0.63625800237619

Ranking 26/20870 scored genes


[Show Scoring Methodology]
The DAMAGES score (disease-associated mutation analysis using gene expression signatures), or D score, was developed to combine evidence from de novo loss-of- function mutation with evidence from cell-type- specific gene expression in the mouse brain (specifically translational profiles of 24 specific mouse CNS cell types isolated from 6 different brain regions). Genes with positive D scores are more likely to be associated with autism risk, with higher-confidence genes having higher D scores. This statistic was first presented by Zhang & Shen (Hum Mutat 38, 204- 215 (2017), and D scores for more than 20,000 RefSeq genes can be found in column M in supplementary table 2 from that paper.
CNVs associated with CNKSR2(1 CNVs)
Xp22.12 10 Deletion-Duplication 13  /  22
Submit New Gene

Report an Error